India's biggest maker of generic drugs will launch a generic version of cholesterol blockbuster Lipitor, which lost US patent protection yesterday.
Ranbaxy has had major manufacturing quality deficiencies since 2006, leading the US Food and Drug Administration to hold up approval of Ranbaxy's version of generic Lipitor.
Lipitor's maker, Pfizer, is splitting revenue from an authorised generic version being sold by partner Watson Pharmaceuticals.
